Genius Sports full-year revenue jumps 31% to $669.5M
Genius Sports (NYSE:GENI) on Wednesday posted a 31% increase in full-year revenue for 2025, reaching $669.5 million.
Mahathir Bayena
Crypto JournalistCrypto journalist for Grafa, with nearly 10 years of experience covering blockchain, Web3, and NFT gaming trends. MBA & Economics grad.
Contact
Contact editorial teamArticles by Mahathir Bayena
Retail
National Vision extends growth streak as Q4 revenue climbs 15%
National Vision Holdings (NASDAQ:EYE) unveiled fourth-quarter and full-year 2025 results on Wednesday, marking its 12th consecutive quarter of positive comparable store sales growth as the optical retailer successfully navigates its post-Walmart transition.
Tartana Minerals advances key copper and zinc projects
Tartana Minerals (ASX:TAT) has highlighted advancements across its portfolio of critical mineral assets.
Clara Resources ramps up Far North Queensland exploration
Clara Resources Australia (ASX:C7A) is ramping up exploration in Far North Queensland's resource-rich Hodgkinson Basin.
AKORA Resources secures Madagascar iron ore permit
AKORA Resources (ASX:AKO) has been granted the mining permit for its flagship Bekisopa High-Grade Iron Ore Project.
Economy
Unions push for five-week annual leave increase
The Australian Council of Trade Unions has formally petitioned the Albanese Government to legislatively increase the nation’s minimum annual leave from four weeks to five.
OD6 Metals secures high-grade Nevada Fluorspar projects
OD6 Metals (ASX:OD6) announced a landmark strategic acquisition of district-scale, ultra high-grade fluorspar projects in Nevada.
Qatar Airways trims Virgin Australia stake
Qatar Airways has divested a 2.05% stake in Virgin Australia (ASX:VGN) just months after formalising a major strategic alliance.
Dreadnought Resources commences drilling at Illaara Gold Project
Dreadnought Resources (ASX:DRE) has commenced an aircore drilling program at its 100% owned Illaara Gold Project.
TScan Therapeutics reports IND clearances for two TCR-T candidates
TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.